TATVA
Tatva Chintan Pharma Chem share price & financials
- Price
- ₹1,194
- Market cap
- ₹3.9k Cr
- Sector
- Chemicals
- Calls analysed
- 6
Tatva Chintan Pharma Chem Limited Q1 FY27
What went well
- Operating revenue of INR 167.1 crores, up 43% YoY and 25% QoQ.
- EBITDA of INR 32.3 crores, up 86% YoY and 15% QoQ.
- First commercial-scale semiconductor product batch successfully qualified by customer, marking a significant achievement.
What to watch
- Electrolyte Salts revenue declined 52% QoQ to INR 6.3 crores due to severe short supply of key raw materials from Middle East crisis.
- Glymes business impacted by aggressive pricing from Chinese suppliers, leading to a decision to withhold further capacity investment.
What Tatva Chintan Pharma Chem Limited does
Tatva Chintan Pharma Chem is an integrated specialty chemicals manufacturer operating across the value chain, producing Phase Transfer Catalysts (PTC), Structure Directing Agents (SDA) used in zeolite synthesis, Electrolyte Salts and Solutions (ESS) for super-capacitor batteries, and Pharmaceutical & Agrochemical Intermediates and other specialty chemicals (PASC) such as Glymes. It sells to pharmaceutical, agrochemical, automotive, electronics and energy-storage industries, earning through direct manufacture and sale of these chemicals rather than contract/tolling work alone. The company uses proprietary process technologies including conventional synthesis, electrolysis and continuous flow chemistry, and supports its global customer base through wholly-owned overseas subsidiaries in the USA and Netherlands.
Segments
- Phase Transfer Catalyst (PTC)
- Structure Directing Agents (SDA)
- Electrolyte Salts and Solutions (ESS)
- Pharmaceuticals and Agrochemicals Intermediates and other Specialty Chemicals (PASC)
- Manufacturing plants
- 2 (Ankleshwar and Dahej SEZ, Gujarat)
- Combined installed capacity
- 791 KL reactor capacity and 39 assembly lines (as of 31 Mar 2026)
- R&D center
- DSIR-approved, 36,000 sq. ft. facility in Vadodara with a team of 56, including 26 senior scientists
- Market position - SDA
- 2nd largest manufacturer of SDAs for zeolites globally; largest commercial supplier in India
- Market position - PTC
- One of India's leading producers with the widest range of PTCs; among key producers globally
- Market position - Electrolyte Salts
- Largest producer of electrolyte salts for super-capacitor batteries in India
Guidance record · Q1 FY27
what the last two calls moved 25 tracked 4 delivered 6 missed 15 open- FY26 Revenue Growth delivered, diluted said Q1 FY26 Promised: upward of 25% Q1 FY27: Promise relates to a completed fiscal year. No new updates.
- SDA Volume Growth went quiet said Q1 FY26 Promised: 40% to 70% Q1 FY27: Promise relates to a completed fiscal year. No new updates.
- Semiconductor Commercialization delayed said Q1 FY26 Promised: slow commercialization to begin in 2027, full-scale by 2029 Q1 FY27: we don't foresee a major commercialization happening until at least I would say not before Q4 of 2028.
All 25 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q1 FY27: revenue up 42.7%, net profit up 128.6% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 83 | 86 | 108 | 117 | 124 +49% | 131 +52% | 134 +24% | 167 +43% |
| EBITDA | 6 | 7 | 9 | 17 | 22 +267% | 25 +257% | 28 +211% | 32 +88% |
| Net profit | -1 | 0 | 1 | 7 | 10 +1100% | 15 | 10 +900% | 16 +129% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +59.7% 1Y
1Y: ₹1,007.3 on 10 Sept 2025 → ₹1,608.7. High ₹1,800.1 (27 Jul 2026), low ₹991.5 (29 Sept 2025).
How the price took the results
close before → close after
- Q1 FY27
- +0.7%
- 17 Jul
- Q4 FY26
- −4.9%
- 16 May
- Q3 FY26
- +0.9%
- 21 Jan
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Financials, as filed
Revenue grew 6.0% a year over 3 years, FY23 to FY26. Operating margin widened to 18.2%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹424 Cr | ₹393 Cr | ₹382 Cr | ₹506 Cr |
| Operating profit | ₹60 Cr | ₹68 Cr | ₹35 Cr | ₹92 Cr |
| Operating margin | 14.2% | 17.3% | 9.2% | 18.2% |
| Interest | ₹7 Cr | ₹6 Cr | ₹0 Cr | ₹2 Cr |
| Depreciation | ₹10 Cr | ₹26 Cr | ₹28 Cr | ₹37 Cr |
| Net profit | ₹46 Cr | ₹31 Cr | ₹5 Cr | ₹42 Cr |
| Net margin | 10.8% | 7.9% | 1.3% | 8.3% |
| Cash from operations | ₹28 Cr | ₹98 Cr | ₹25 Cr | ₹31 Cr |
| Free cash flow | ₹-175 Cr | ₹-30 Cr | ₹-51 Cr | ₹-82 Cr |
| ROCE | 9.0% | 7.0% | 1.0% | 7.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹20 Cr | ₹22 Cr | ₹22 Cr | ₹23 Cr | ₹23 Cr | ₹23 Cr |
| Reserves | ₹146 Cr | ₹451 Cr | ₹493 Cr | ₹714 Cr | ₹731 Cr | ₹758 Cr |
| Borrowings | ₹90 Cr | ₹120 Cr | ₹170 Cr | ₹14 Cr | ₹83 Cr | ₹120 Cr |
| Other liabilities | ₹59 Cr | ₹65 Cr | ₹74 Cr | ₹67 Cr | ₹70 Cr | ₹102 Cr |
| Total liabilities | ₹315 Cr | ₹658 Cr | ₹759 Cr | ₹819 Cr | ₹908 Cr | ₹1.0k Cr |
| Fixed assets | ₹120 Cr | ₹160 Cr | ₹196 Cr | ₹427 Cr | ₹515 Cr | ₹611 Cr |
| Capital work in progress | ₹10 Cr | ₹51 Cr | ₹231 Cr | ₹77 Cr | ₹80 Cr | ₹23 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹10 Cr | ₹0 Cr | ₹4 Cr |
| Other assets | ₹185 Cr | ₹447 Cr | ₹332 Cr | ₹305 Cr | ₹312 Cr | ₹365 Cr |
| Total assets | ₹315 Cr | ₹658 Cr | ₹759 Cr | ₹819 Cr | ₹908 Cr | ₹1.0k Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Mutual funds in TATVA
Filings to Aug 2026
0 new, 0 added, 0 trimmed, 0 sold out — net +0.00 L shares (+0.0%).
- Held by funds
- ₹84 Cr
- 1 schemes
- Biggest holder
- Nippon India ELSS Tax Saver Fund
- ₹84 Cr · 0.6% of that fund
| Scheme | Holding | Last month | Held since |
|---|---|---|---|
| Nippon India ELSS Tax Saver Fund Nippon India Mutual Fund | ₹84 Cr | held | Apr '22 |
HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.
Mutual funds Aug 2026
0 added, 0 trimmed — net 0 shares (+0.0%)
- Funds are sitting on
- -44%
- vs est. average cost
- Held by funds
- ₹84 Cr
- 1 schemes · ≈ 1.6% of the company
Shares held by these funds −76%
Aug '23 5.17 L shares Jul '26
All earnings calls (4)
Read the Q1 FY27 call →Learn to analyse Tatva Chintan Pharma Chem Limited
Guides on how to read this kind of business and the numbers that matter.